Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 44.15
(-2.11%)
HKD 44.15
(-2.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.96 Billion CNY | -35.17% |
| 2022 | -5.15 Billion CNY | 11.18% |
| 2021 | -5.79 Billion CNY | -174.31% |
| 2020 | -2.11 Billion CNY | -385.79% |
| 2019 | -435.25 Million CNY | 30.91% |
| 2018 | -629.97 Million CNY | 24.94% |
| 2017 | -839.28 Million CNY | 6.5% |
| 2016 | -897.58 Million CNY | -385.24% |
| 2015 | -184.97 Million CNY | -148.73% |
| 2014 | -74.36 Million CNY | -232.97% |
| 2013 | -22.33 Million CNY | -437.44% |
| 2012 | -4.15 Million CNY | 96.09% |
| 2011 | -106.42 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -7.4 Billion CNY | -6.34% |
| 2024 Q2 | -5.51 Billion CNY | 25.53% |
| 2024 Q3 | -5.2 Billion CNY | 7.2% |
| 2023 Q4 | -6.96 Billion CNY | 0.14% |
| 2023 Q2 | -6.9 Billion CNY | -20.08% |
| 2023 FY | -6.96 Billion CNY | -35.17% |
| 2023 Q3 | -6.97 Billion CNY | -0.94% |
| 2023 Q1 | -5.75 Billion CNY | -11.67% |
| 2022 Q3 | -6.2 Billion CNY | -8.9% |
| 2022 FY | -5.15 Billion CNY | 11.18% |
| 2022 Q4 | -5.15 Billion CNY | 17.02% |
| 2022 Q2 | -5.7 Billion CNY | -9.53% |
| 2022 Q1 | -5.2 Billion CNY | 10.27% |
| 2021 Q1 | -1.98 Billion CNY | 5.98% |
| 2021 Q2 | -581.23 Million CNY | 70.76% |
| 2021 Q4 | -5.79 Billion CNY | -1411.39% |
| 2021 FY | -5.79 Billion CNY | -174.31% |
| 2021 Q3 | -383.75 Million CNY | 33.98% |
| 2020 Q3 | -2.37 Billion CNY | -1542.53% |
| 2020 Q1 | -380.91 Million CNY | 12.48% |
| 2020 Q4 | -2.11 Billion CNY | 11.0% |
| 2020 Q2 | -144.64 Million CNY | 62.03% |
| 2020 FY | -2.11 Billion CNY | -385.79% |
| 2019 FY | -435.25 Million CNY | 30.91% |
| 2019 Q2 | -217.66 Million CNY | 63.6% |
| 2019 Q1 | -598.02 Million CNY | 5.07% |
| 2019 Q3 | -279.34 Million CNY | -28.33% |
| 2019 Q4 | -435.25 Million CNY | -55.81% |
| 2018 Q2 | -727.44 Million CNY | 13.7% |
| 2018 FY | -629.97 Million CNY | 24.94% |
| 2018 Q4 | -629.97 Million CNY | -107.04% |
| 2018 Q3 | -304.27 Million CNY | 58.17% |
| 2018 Q1 | -842.91 Million CNY | -0.43% |
| 2017 Q4 | -839.28 Million CNY | 15.71% |
| 2017 Q1 | -1.16 Billion CNY | -30.04% |
| 2017 Q2 | -1.02 Billion CNY | 11.79% |
| 2017 Q3 | -995.76 Million CNY | 3.28% |
| 2017 FY | -839.28 Million CNY | 6.5% |
| 2016 Q1 | 293.98 Million CNY | 258.93% |
| 2016 Q3 | -205.95 Million CNY | -1.62% |
| 2016 Q4 | -897.58 Million CNY | -335.82% |
| 2016 Q2 | -202.66 Million CNY | -168.94% |
| 2016 FY | -897.58 Million CNY | -385.24% |
| 2015 FY | -184.97 Million CNY | -148.73% |
| 2015 Q4 | -184.97 Million CNY | 0.0% |
| 2014 FY | -74.36 Million CNY | -232.97% |
| 2013 FY | -22.33 Million CNY | -437.44% |
| 2012 FY | -4.15 Million CNY | 96.09% |
| 2011 FY | -106.42 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -9017.231% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 232.201% |